Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
EGFR negative
i
Other names:
EGFR, ERBB, ERBB1, Epidermal growth factor receptor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
1956
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
EGFR exon 19 deletion (79)
EGFR amplification (52)
EGFR exon 18 deletion (3)
EGFR exon 2-7 deletion + EGFR amplification (2)
EGFR amplification + ERBB2 amplification (1)
EGFR exon 19 deletion + HER-2 amplification (1)
EGFR exon 21 deletion (1)
EGFR T790M + exon 19 deletion (0)
EGFR amplifcation (0)
EGFR exon 19 deletion (79)
EGFR amplification (52)
EGFR exon 18 deletion (3)
EGFR exon 2-7 deletion + EGFR amplification (2)
EGFR amplification + ERBB2 amplification (1)
EGFR exon 19 deletion + HER-2 amplification (1)
EGFR exon 21 deletion (1)
EGFR T790M + exon 19 deletion (0)
EGFR amplifcation (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
EGFR negative
Non Small Cell Lung Cancer
EGFR negative
Non Small Cell Lung Cancer
pembrolizumab + atezolizumab
Sensitive: B - Late Trials
pembrolizumab + atezolizumab
Sensitive
:
B
pembrolizumab + atezolizumab
Sensitive: B - Late Trials
pembrolizumab + atezolizumab
Sensitive
:
B
EGFR negative
Non Small Cell Lung Cancer
EGFR negative
Non Small Cell Lung Cancer
anlotinib + sintilimab
Sensitive: C2 – Inclusion Criteria
anlotinib + sintilimab
Sensitive
:
C2
anlotinib + sintilimab
Sensitive: C2 – Inclusion Criteria
anlotinib + sintilimab
Sensitive
:
C2
EGFR negative
Non Small Cell Lung Cancer
EGFR negative
Non Small Cell Lung Cancer
anlotinib
Sensitive: C2 – Inclusion Criteria
anlotinib
Sensitive
:
C2
anlotinib
Sensitive: C2 – Inclusion Criteria
anlotinib
Sensitive
:
C2
EGFR negative
Non Small Cell Lung Cancer
EGFR negative
Non Small Cell Lung Cancer
sintilimab
Sensitive: C2 – Inclusion Criteria
sintilimab
Sensitive
:
C2
sintilimab
Sensitive: C2 – Inclusion Criteria
sintilimab
Sensitive
:
C2
EGFR negative
Non Small Cell Lung Cancer
EGFR negative
Non Small Cell Lung Cancer
afatinib
Sensitive: C3 – Early Trials
afatinib
Sensitive
:
C3
afatinib
Sensitive: C3 – Early Trials
afatinib
Sensitive
:
C3
EGFR negative
Lung Non-Squamous Non-Small Cell Cancer
EGFR negative
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
bevacizumab
Sensitive: C3 – Early Trials
bevacizumab
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login